Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years
The risk of skeletal adverse events with zoledronic acid
Do we need to stratify follicular lymphoma (FL) patients for treatment?
Best treatment strategy for FLT3 ITD AML
Financial benefit of combining two expensive drugs for CLL